

# Interplay between $\hat{\text{I}}^2$ -lactamases and new $\hat{\text{I}}^2$ -lactamase

Nature Reviews Microbiology

17, 295-306

DOI: [10.1038/s41579-019-0159-8](https://doi.org/10.1038/s41579-019-0159-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular Basis of Class A $\beta$ -Lactamase Inhibition by Relebactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	45
2	Detection of carbapenemase-producing Enterobacterales and the BD Phoenix CPO Detect panel. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 659-665.	1.5	4
3	Structure-Based Development of (1-(3- $\beta$ -Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine- $\beta$ -lactamases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7160-7184.	2.9	41
4	Synthesis of Cyclic $N$ -Hydroxylated Ureas and Oxazolidinone Oximes Enabled by Chemoselective Iodine(III)-Mediated Radical or Cationic Cyclizations of Unsaturated $N$ -Alkoxyureas. <i>Advanced Synthesis and Catalysis</i> , 2019, 361, 5160-5169.	2.1	16
5	Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo- $\beta$ -Lactamase Inhibitors. <i>Molecules</i> , 2019, 24, 1174.	1.7	7
6	Repurposing Peptidomimetic as Potential Inhibitor of New Delhi Metallo- $\beta$ -lactamases in Gram-Negative Bacteria. <i>ACS Infectious Diseases</i> , 2019, 5, 2061-2066.	1.8	13
7	Impact of relebactam-mediated inhibition of <i>Mycobacterium abscessus</i> BlaMab $\beta$ -lactamase on the in vitro and intracellular efficacy of imipenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 379-383.	1.3	3
8	Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine- $\beta$ -Lactamases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8544-8556.	2.9	139
9	MeLAD: an integrated resource for metalloenzyme-ligand associations. <i>Bioinformatics</i> , 2020, 36, 904-909.	1.8	23
10	Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations. <i>Current Infectious Disease Reports</i> , 2019, 21, 39.	1.3	21
11	The latest advances in $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2169-2184.	0.9	89
12	TiO <sub>2</sub> photocatalysis under natural solar radiation for the degradation of the carbapenem antibiotics imipenem and meropenem in aqueous solutions at pilot plant scale. <i>Water Research</i> , 2019, 166, 115037.	5.3	67
13	Structure-based classification of class A beta-lactamases, an update. <i>Current Research in Translational Medicine</i> , 2019, 67, 115-122.	1.2	20
14	The role of new $\beta$ -lactamase inhibitors in gram-negative infections. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 638-646.	1.3	27
15	Efficacy of antibiotics in acute appendicitis treatment. <i>American Journal of Surgery</i> , 2020, 219, 690.	0.9	0
16	$\beta$ -Lactamase Inhibitors To Restore the Efficacy of Antibiotics against Superbugs. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1859-1881.	2.9	99
17	Simultaneous achievement of high strength and high ductility in copper matrix composites with carbon nanotubes/Cu composite foams as reinforcing skeletons. <i>Nanotechnology</i> , 2020, 31, 045701.	1.3	15
18	The transferability and evolution of NDM-1 and KPC-2 co-producing <i>Klebsiella pneumoniae</i> from clinical settings. <i>EBioMedicine</i> , 2020, 51, 102599.	2.7	87

#	ARTICLE	IF	CITATIONS
19	VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo- $\beta$ -Lactamases, Restores Activity of Cefepime in <i>Enterobacteriales</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	123
20	The global preclinical antibacterial pipeline. <i>Nature Reviews Microbiology</i> , 2020, 18, 275-285.	13.6	442
21	Overcoming $\beta$ -Lactam resistance in <i>Pseudomonas aeruginosa</i> using non-canonical tobramycin-based antibiotic adjuvants. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127575.	1.0	11
22	Enzyme-targeted fluorescent small-molecule probes for bacterial imaging. <i>Current Opinion in Chemical Biology</i> , 2020, 57, 155-165.	2.8	21
23	Design, synthesis, biological evaluation and in silico studies of certain aryl sulfonyl hydrazones conjugated with 1,3-diaryl pyrazoles as potent metallo- $\beta$ -lactamase inhibitors. <i>Bioorganic Chemistry</i> , 2020, 105, 104386.	2.0	16
24	Piperacillin/tazobactam resistance in a clinical isolate of <i>Escherichia coli</i> due to IS26-mediated amplification of blaTEM-1B. <i>Nature Communications</i> , 2020, 11, 4915.	5.8	50
25	Structure-based design of covalent inhibitors targeting metallo- $\beta$ -lactamases. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112573.	2.6	7
26	1,2,3-Triazole $\beta$ -lactam conjugates as antimicrobial agents. <i>Heliyon</i> , 2020, 6, e04241.	1.4	13
27	Metallo- $\beta$ -lactamases: a review. <i>Molecular Biology Reports</i> , 2020, 47, 6281-6294.	1.0	64
28	Can We Exploit $\beta$ -Lactamases Intrinsic Dynamics for Designing More Effective Inhibitors?. <i>Antibiotics</i> , 2020, 9, 833.	1.5	6
29	<i>Streptococcus gordonii</i> : Pathogenesis and Host Response to Its Cell Wall Components. <i>Microorganisms</i> , 2020, 8, 1852.	1.6	40
30	Genome-based characterization of two Colombian clinical <i>Providencia rettgeri</i> isolates co-harboring NDM-1, VIM-2, and other $\beta$ -lactamases. <i>BMC Microbiology</i> , 2020, 20, 345.	1.3	12
31	Molecular Mechanisms, Epidemiology, and Clinical Importance of $\beta$ -Lactam Resistance in <i>Enterobacteriaceae</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 5090.	1.8	60
32	Recent advances in the development of $\beta$ -lactamase inhibitors. <i>Journal of Microbiology</i> , 2020, 58, 633-647.	1.3	17
33	4-(N-Alkyl- and -Acyl-amino)-1,2,4-triazole-3-thione Analogs as Metallo- $\beta$ -Lactamase Inhibitors: Impact of 4-Linker on Potency and Spectrum of Inhibition. <i>Biomolecules</i> , 2020, 10, 1094.	1.8	15
34	ANT2681: SAR Studies Leading to the Identification of a Metallo- $\beta$ -lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i> . <i>ACS Infectious Diseases</i> , 2020, 6, 2419-2430.	1.8	31
35	In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	14
36	Graphene Oxide Quantum Dot-Based Functional Nanomaterials for Effective Antimicrobial Applications. <i>Chemical Record</i> , 2020, 20, 1505-1515.	2.9	9

#	ARTICLE	IF	CITATIONS
37	Discovery of mercaptopropanamide-substituted aryl tetrazoles as new broad-spectrum metallo- $\beta$ -lactamase inhibitors. <i>RSC Advances</i> , 2020, 10, 31377-31384.	1.7	5
38	Antibacterial Activity of Nitrogen-Doped Carbon Dots Enhanced by Atomic Dispersion of Copper. <i>Langmuir</i> , 2020, 36, 11629-11636.	1.6	32
39	<i>In Vitro</i> Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	40
40	$\beta$ -Lactamase triggered visual detection of bacteria using cephalosporin functionalized biomaterials. <i>Chemical Communications</i> , 2020, 56, 11098-11101.	2.2	9
41	Developing Diagnostic and Therapeutic Approaches to Bacterial Infections for a New Era: Implications of Globalization. <i>Antibiotics</i> , 2020, 9, 916.	1.5	11
42	Analysis of $\beta$ -lactone formation by clinically observed carbapenemases informs on a novel antibiotic resistance mechanism. <i>Journal of Biological Chemistry</i> , 2020, 295, 16604-16613.	1.6	12
43	Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	31
44	NMR Characterization of the Influence of Zinc(II) Ions on the Structural and Dynamic Behavior of the New Delhi Metallo- $\beta$ -Lactamase-1 and on the Binding with Flavonols as Inhibitors. <i>ACS Omega</i> , 2020, 5, 10466-10480.	1.6	19
45	Diversity and abundance of resistome in rhizosphere soil. <i>Science China Life Sciences</i> , 2020, 63, 1946-1949.	2.3	1
46	Antimicrobial Resistance in ESKAPE Pathogens. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	898
47	Systematic research of H2dedpa derivatives as potent inhibitors of New Delhi Metallo- $\beta$ -lactamase-1. <i>Bioorganic Chemistry</i> , 2020, 101, 103965.	2.0	5
48	Ruthenium-Catalyzed <i>meta</i> -Selective C-H Nitration of Biologically Important Aryltetrazoles. <i>Advanced Synthesis and Catalysis</i> , 2020, 362, 2984-2989.	2.1	16
49	Scaffold Hopping Computational Approach for Searching Novel $\beta$ -Lactamase Inhibitors. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2020, 14, 127-135.	0.2	0
50	<i>In Vitro</i> Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant <i>Enterobacterales</i> with Varying Intrinsic and Acquired Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	25
51	Metallo- $\beta$ -Lactamase Inhibitors Inspired on Snapshots from the Catalytic Mechanism. <i>Biomolecules</i> , 2020, 10, 854.	1.8	50
52	Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo- $\beta$ -lactamases. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115598.	1.4	10
53	In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2616-2621.	1.3	44
54	In vitro activity of the novel $\beta$ -lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1850-1858.	1.3	32

#	ARTICLE	IF	CITATIONS
55	Epidemiology of $\beta$ -Lactamase-Producing Pathogens. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	425
56	A novel fluorescent probe for the detection of AmpC beta-lactamase and the application in screening beta-lactamase inhibitors. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2020, 234, 118257.	2.0	0
57	6-Arylmethylidene Penicillin-Based Sulfone Inhibitors for Repurposing Antibiotic Efficiency in Priority Pathogens. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3737-3755.	2.9	11
58	Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D $\beta$ -Lactamases. <i>Biomolecules</i> , 2020, 10, 483.	1.8	7
59	Specific NDM-1 Inhibitor of Isoliquiritin Enhances the Activity of Meropenem against NDM-1-positive Enterobacteriaceae in vitro. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2162.	1.2	13
60	The $\beta$ -Lactamase Inhibitor Boronic Acid Derivative SM23 as a New Anti-Pseudomonas aeruginosa Biofilm. <i>Frontiers in Microbiology</i> , 2020, 11, 35.	1.5	22
61	Mechanical penetration of $\beta$ -lactamase-resistant Gram-negative bacteria by programmable nanowires. <i>Science Advances</i> , 2020, 6, .	4.7	23
62	Discovery and characterization of New Delhi metallo- $\beta$ -lactamase-1 inhibitor peptides that potentiate meropenem-dependent killing of carbapenemase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2843-2851.	1.3	13
63	Principles and current strategies targeting metallo- $\beta$ -lactamase mediated antibacterial resistance. <i>Medicinal Research Reviews</i> , 2020, 40, 1558-1592.	5.0	42
64	In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105925.	1.1	29
65	Suppression of $\beta$ -Lactam Resistance by Aspergillomarasmine A Is Influenced by both the Metallo- $\beta$ -Lactamase Target and the Antibiotic Partner. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
66	Cyclic boronates as versatile scaffolds for KPC-2 $\beta$ -lactamase inhibition. <i>RSC Medicinal Chemistry</i> , 2020, 11, 491-496.	1.7	20
67	Preparation and Mechanistic Studies of 2-Substituted Bisthiazolidines by Imine Exchange. <i>European Journal of Organic Chemistry</i> , 2020, 2020, 1084-1092.	1.2	4
68	In vitro activity of AST-120 that suppresses indole signaling in Escherichia coli, which attenuates drug tolerance and virulence. <i>PLoS ONE</i> , 2020, 15, e0232461.	1.1	11
69	Diazabicyclooctane Functionalization for Inhibition of $\beta$ -Lactamases from Enterobacteria. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5257-5273.	2.9	17
70	In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1859-1873.	1.3	11
71	Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	72
72	Biochemical Activity of Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	48

#	ARTICLE	IF	CITATIONS
73	Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of <i>Enterobacteriales</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> Complex. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	16
74	Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> . 2020. 64. .	1.4	32
75	Iminodiacetic Acid as a Novel Metallo-Binding Pharmacophore for New Delhi Metallo- $\beta$ -Lactamase Inhibitor Development. <i>ChemMedChem</i> , 2020, 15, 1272-1282.	1.6	17
76	Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 705-720.	2.0	14
77	Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo- $\beta$ -Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance. <i>MBio</i> , 2020, 11, .	1.8	30
78	In vitro activity of aztreonam/avibactam against a global collection of <i>Klebsiella pneumoniae</i> collected from defined culture sources in 2016 and 2017. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 14-22.	0.9	9
79	Desirable drug-drug interactions or when a matter of concern becomes a renewed therapeutic strategy. <i>Drug Discovery Today</i> , 2021, 26, 315-328.	3.2	8
80	Polypyridine ligands as potential metallo- $\beta$ -lactamase inhibitors. <i>Journal of Inorganic Biochemistry</i> , 2021, 215, 111315.	1.5	7
81	Performance of the BD Phoenix CPO detect assay for detection and classification of carbapenemase-producing organisms. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 979-985.	1.3	7
82	Benzimidazole and Benzoxazole Zinc Chelators as Inhibitors of Metallo- $\beta$ -Lactamase NDM-1. <i>ChemMedChem</i> , 2021, 16, 654-661.	1.6	9
83	Interactions of the Diazabicyclooctane Serine $\beta$ -Lactamase Inhibitor ETX1317 with Target Enzymes. <i>ACS Infectious Diseases</i> , 2021, 7, 114-122.	1.8	9
84	Ceftazidime-Avibactam Resistance Mutations V240G, D179Y, and D179Y/T243M in KPC-3 $\beta$ -Lactamase Do Not Alter Cefpodoxime-ETX1317 Susceptibility. <i>ACS Infectious Diseases</i> , 2021, 7, 79-87.	1.8	21
85	In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic <i>Burkholderia</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	5
86	Highly Oxidized $\beta$ -Lactam-Containing Natural Products: Total Synthesis and Biological Evaluation. <i>Heterocycles</i> , 2021, 102, 1235.	0.4	3
87	Inhibition of the <i>Clostridioides difficile</i> Class D $\beta$ -Lactamase CDD-1 by Avibactam. <i>ACS Infectious Diseases</i> , 2021, 7, 1164-1176.	1.8	2
88	Catalytic mechanism of the colistin resistance protein MCR-1. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 3813-3819.	1.5	11
89	Enhancing bactericidal strategy with selected aromatic compounds: <i>in vitro</i> and <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 5547-5555.	2.0	3
90	$\beta$ -Lactam Antibiotics. , 2021, , 1-10.		0

#	ARTICLE	IF	CITATIONS
91	Importance of microbial secondary metabolites in health care applications. , 2021, , 349-383.		0
92	Drug repurposing for next-generation combination therapies against multidrug-resistant bacteria. <i>Theranostics</i> , 2021, 11, 4910-4928.	4.6	70
93	Antimicrobial Effect of a Novel Chitosan Derivative and Its Synergistic Effect with Antibiotics. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 3237-3245.	4.0	57
94	The Whole Is Bigger than the Sum of Its Parts: Drug Transport in the Context of Two Membranes with Active Efflux. <i>Chemical Reviews</i> , 2021, 121, 5597-5631.	23.0	31
95	Enlarging the Toolbox Against Antimicrobial Resistance: Aptamers and CRISPR-Cas. <i>Frontiers in Microbiology</i> , 2021, 12, 606360.	1.5	6
96	Aerobacterial Vaginosis among Women Attending an Infertility Clinic at a Tertiary Care Hospital in Chennai, India and Susceptibility Pattern of Isolates. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 194-200.	0.3	1
97	Bicyclic Boronate $\beta$ -Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens. <i>Advanced Therapeutics</i> , 2021, 4, 2000246.	1.6	12
98	Detection of Extended-Spectrum $\beta$ -Lactamases among <i>Acinetobacter Baumannii</i> Isolated from Hospitals of Qazvin, Iran. <i>Ethiopian Journal of Health Sciences</i> , 2021, 31, 229-236.	0.2	2
99	Correlation between the Antibiotic Resistance Genes and Susceptibility to Antibiotics among the Carbapenem-Resistant Gram-Negative Pathogens. <i>Antibiotics</i> , 2021, 10, 255.	1.5	10
100	Study on carbapenemase-producing bacteria by matrix-assisted laser desorption/ionization approach. <i>PLoS ONE</i> , 2021, 16, e0247369.	1.1	7
101	<i>In Crystallo</i> Time-Resolved Interaction of the <i>Clostridioides difficile</i> CDD-1 enzyme with Avibactam Provides New Insights into the Catalytic Mechanism of Class D $\beta$ -lactamases. <i>ACS Infectious Diseases</i> , 2021, 7, 1765-1776.	1.8	5
102	Multimodal Interventions to Prevent and Control Carbapenem-Resistant Enterobacteriaceae and Extended-Spectrum $\beta$ -Lactamase Producer-Associated Infections at a Tertiary Care Hospital in Egypt. <i>Antibiotics</i> , 2021, 10, 509.	1.5	8
103	Mastering the Gram-negative bacterial barrier – Chemical approaches to increase bacterial bioavailability of antibiotics. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 339-360.	6.6	42
104	Structural Basis of Metallo- $\beta$ -lactamase Inhibition by <i>N</i> -Sulfamoylpyrrole-2-carboxylates. <i>ACS Infectious Diseases</i> , 2021, 7, 1809-1817.	1.8	17
105	Antimicrobial Resistance Conferred by OXA-48 $\beta$ -Lactamases: Towards a Detailed Mechanistic Understanding. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	15
106	Emergence of transferable ceftazidime-avibactam resistance in KPC-producing <i>Klebsiella pneumoniae</i> due to a novel CMY AmpC $\beta$ -lactamase in China. <i>Clinical Microbiology and Infection</i> , 2022, 28, 136.e1-136.e6.	2.8	13
107	Multidrug-resistant <i>Klebsiella pneumoniae</i> : mechanisms of resistance including updated data for novel $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1457-1468.	2.0	28
108	Co-occurrence of Carbapenemase-encoding Genes Among <i>Klebsiella pneumoniae</i> Clinical Isolates: Positive Relationship of bla NDM and bla SIM with Imipenem Resistance. <i>Jundishapur Journal of Microbiology</i> , 2021, 14, .	0.2	3



#	ARTICLE	IF	CITATIONS
109	Discovery of Novel Chemical Series of OXA-48 $\beta$ -Lactamase Inhibitors by High-Throughput Screening. <i>Pharmaceuticals</i> , 2021, 14, 612.	1.7	4
110	Metallo- $\beta$ -lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design. <i>Chemical Reviews</i> , 2021, 121, 7957-8094.	23.0	114
111	Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable $\beta$ -Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10155-10166.	2.9	17
112	Detection of carbapenemase producing enterobacteria using an ion sensitive field effect transistor sensor. <i>Scientific Reports</i> , 2021, 11, 12061.	1.6	4
113	Pharmacokinetics of Non- $\beta$ -Lactam $\beta$ -Lactamase Inhibitors. <i>Antibiotics</i> , 2021, 10, 769.	1.5	11
114	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo- $\beta$ -lactamases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 41, 127956.	1.0	13
115	Enzyme-catalyzed biodegradation of penicillin fermentation residues by $\beta$ -lactamase OtLac from <i>Ochrobactrum tritici</i> . <i>Microbial Cell Factories</i> , 2021, 20, 117.	1.9	6
116	Spectroscopic and biochemical characterization of metallo- $\beta$ -lactamase IMP-1 with dicarboxylic, sulfonyl, and thiol inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 40, 116183.	1.4	5
117	Antimicrobial Resistance and Extended-Spectrum Beta-Lactamase (ESBL) Genes in <i>E. coli</i> Isolated from Equine Fecal Samples in Turkey. <i>Journal of Equine Veterinary Science</i> , 2021, 101, 103461.	0.4	4
118	Carbapenemase producing <i>Klebsiella pneumoniae</i> : implication on future therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 53-69.	2.0	25
119	Synthesis of Arylidene- $\beta$ -lactams via <i>exo</i> -Selective Matsuda-Heck Arylation of Methylene- $\beta$ -lactams. <i>Journal of Organic Chemistry</i> , 2021, 86, 8786-8796.	1.7	7
120	Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible <i>Enterobacterales</i> Collected as Part of a Global Surveillance Program, 2012 to 2017. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0200020.	1.4	61
121	High prevalence of blaCTX-M and blaSHV among ESBL producing <i>E. coli</i> isolates from beef cattle in China's Sichuan-Chongqing Circle. <i>Scientific Reports</i> , 2021, 11, 13725.	1.6	10
122	Novel $\beta$ -Lactamase Inhibitors: New Weapons in the Arms Race against Antimicrobial Resistance. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 119-125.	0.4	4
123	Co-Existence of Certain ESBLs, MBLs and Plasmid Mediated Quinolone Resistance Genes among MDR <i>E. coli</i> Isolated from Different Clinical Specimens in Egypt. <i>Antibiotics</i> , 2021, 10, 835.	1.5	19
124	Molecular epidemiology of cefotaxime-resistant but ceftazidime-susceptible Enterobacterales and evaluation of the in vitro bactericidal activity of ceftazidime and cefepime. <i>Brazilian Journal of Microbiology</i> , 2021, 52, 1853-1863.	0.8	2
125	The urgent need for metallo- $\beta$ -lactamase inhibitors: an unattended global threat. <i>Lancet Infectious Diseases</i> , 2022, 22, e28-e34.	4.6	103
126	Sigmoid <i>E</i> Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0092621.	1.4	5



#	ARTICLE	IF	CITATIONS
127	Durlobactam, a New Diazabicyclooctane $\beta$ -Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam. <i>Frontiers in Microbiology</i> , 2021, 12, 709974.	1.5	39
128	QPX7728, An Ultra-Broad-Spectrum $\beta$ -Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. <i>Frontiers in Microbiology</i> , 2021, 12, 697180.	1.5	25
129	2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo- $\beta$ -Lactamase Classes by Maintaining a Conserved Binding Mode. <i>ACS Infectious Diseases</i> , 2021, 7, 2697-2706.	1.8	16
131	Towards the sustainable discovery and development of new antibiotics. <i>Nature Reviews Chemistry</i> , 2021, 5, 726-749.	13.8	439
132	Molecular Basis of Bicyclic Boronate $\beta$ -Lactamase Inhibitors of Ultrabroad Efficacy – Insights From Molecular Dynamics Simulation Studies. <i>Frontiers in Microbiology</i> , 2021, 12, 721826.	1.5	2
133	<i>Stenotrophomonas maltophilia</i> bacteraemia: 61 cases in a tertiary hospital in Denmark. <i>Infectious Diseases</i> , 2022, 54, 26-35.	1.4	6
134	Modulation of a Mycobacterial ADP-Ribosyltransferase to Augment Rifamycin Antibiotic Resistance. <i>ACS Infectious Diseases</i> , 2021, 7, 2604-2611.	1.8	8
135	The multiple benefits of second-generation $\beta$ -lactamase inhibitors in treatment of multidrug-resistant bacteria. <i>Infectious Diseases Now</i> , 2021, 51, 510-517.	0.7	8
136	Rational design of a new antibiotic class for drug-resistant infections. <i>Nature</i> , 2021, 597, 698-702.	13.7	69
137	Kinetic and Structural Characterization of the First B3 Metallo- $\beta$ -Lactamase with an Active-Site Glutamic Acid. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0093621.	1.4	7
138	On the Offensive: the Role of Outer Membrane Vesicles in the Successful Dissemination of New Delhi Metallo- $\beta$ -lactamase (NDM-1). <i>MBio</i> , 2021, 12, e0183621.	1.8	17
139	The Prevalence and Characterization of Fecal Extended-Spectrum-Beta-Lactamase-Producing <i>Escherichia coli</i> Isolated from Pigs on Farms of Different Sizes in Latvia. <i>Antibiotics</i> , 2021, 10, 1099.	1.5	3
140	Practical Agar-Based Disk Diffusion Tests Using Sulfamoyl Heteroarylcarboxylic Acids for Identification of Subclass B1 Metallo- $\beta$ -Lactamase-Producing <i>Enterobacterales</i> . <i>Journal of Clinical Microbiology</i> , 2021, 59, e0076121.	1.8	0
141	Rapid Detection of Multiple Classes of $\beta$ -Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. <i>Antibiotics</i> , 2021, 10, 1110.	1.5	4
142	H2dpa derivatives containing pentadentate ligands: An acyclic adjuvant potentiates meropenem activity in vitro and in vivo against metallo- $\beta$ -lactamase-producing <i>Enterobacterales</i> . <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113702.	2.6	12
143	Rapid personalized AMR diagnostics using two-dimensional antibiotic resistance profiling strategy employing a thermometric NDM-1 biosensor. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113526.	5.3	6
144	Epidemiology and Mechanisms of Ceftazidime – Avibactam Resistance in Gram-Negative Bacteria. <i>Engineering</i> , 2021, , .	3.2	13
145	2-Mercaptomethyl-thiazolidines use conserved aromatic S interactions to achieve broad-range inhibition of metallo- $\beta$ -lactamases. <i>Chemical Science</i> , 2021, 12, 2898-2908.	3.7	24



#	ARTICLE	IF	CITATIONS
170	Adaptive Role of Cell Death in Yeast Communities Stressed with Macrolide Antifungals. <i>MSphere</i> , 2021, 6, e0074521.	1.3	3
171	In Vitro Activity Comparison of Ceftazidime+Avibactam and Aztreonam+Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 780365.	1.8	12
172	Classification of the metallo- $\beta$ -lactamase subtype produced by the carbapenem-resistant <i>Pseudomonas aeruginosa</i> isolates in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 170-175.	0.8	1
173	$\beta$ -Lactam Antibiotics. , 2021, , 911-920.		0
174	Polymers as advanced antibacterial and antibiofilm agents for direct and combination therapies. <i>Chemical Science</i> , 2022, 13, 345-364.	3.7	74
175	Genomic characterization of triple-carbapenemase-producing <i>Acinetobacter baumannii</i> . <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab191.	0.9	3
176	Profile variation of bla genes among non-lactose fermenting Gram-negative bacilli between clinical and environmental isolates of Dr. Soetomo Hospital, Surabaya, Indonesia. <i>Biodiversitas</i> , 2021, 22, .	0.2	2
177	Imitation of $\beta$ -lactam binding enables broad-spectrum metallo- $\beta$ -lactamase inhibitors. <i>Nature Chemistry</i> , 2022, 14, 15-24.	6.6	39
178	Novel metallo- $\beta$ -lactamase inhibitors. <i>Nature Reviews Microbiology</i> , 2021, , .	13.6	1
180	Genetic Dissection of Antibiotic Adjuvant Activity. <i>MBio</i> , 2022, 13, e0308421.	1.8	12
181	<i>Brenneria goodwinii</i> growth in vitro is improved by competitive interactions with other bacterial species associated with Acute Oak Decline. <i>Current Research in Microbial Sciences</i> , 2022, 3, 100102.	1.4	4
182	High-Throughput Screen for Inhibitors of <i>Klebsiella pneumoniae</i> Virulence Using a <i>Tetrahymena pyriformis</i> Co-Culture Surrogate Host Model. <i>ACS Omega</i> , 2022, 7, 5401-5414.	1.6	3
183	Graphene quantum dots: A contemporary perspective on scope, opportunities, and sustainability. <i>Renewable and Sustainable Energy Reviews</i> , 2022, 157, 111993.	8.2	41
184	Beta lactam. , 2022, , 3-63.		2
185	Challenge of evolving <i>Klebsiella pneumoniae</i> infection in patients on hemodialysis: from the classic strain to the carbapenem-resistant hypervirulent one. <i>International Journal of Medical Sciences</i> , 2022, 19, 416-424.	1.1	6
186	Drug Repurposing of the Unithiol: Inhibition of Metallo- $\beta$ -Lactamases for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Infections. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1834.	1.8	5
187	Prevalence and Therapeutic Management of Infections by Multi-Drug-Resistant Organisms (MDROs) in Patients with Liver Cirrhosis: A Narrative Review. <i>Antibiotics</i> , 2022, 11, 232.	1.5	3
188	Targeting Metalloenzymes by Boron-Containing Metal-Binding Pharmacophores. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17706-17727.	2.9	13

#	ARTICLE	IF	CITATIONS
189	Infectious Diseases Society of America Guidance on the Treatment of AmpC $\beta$ -Lactamase-Producing Enterobacterales, Carbapenem-Resistant <i>Acinetobacter baumannii</i> , and <i>Stenotrophomonas maltophilia</i> Infections. <i>Clinical Infectious Diseases</i> , 2022, 74, 2089-2114.	2.9	262
190	Surgical Antibiotic Prophylaxis in an Era of Antibiotic Resistance: Common Resistant Bacteria and Wider Considerations for Practice. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5235-5252.	1.1	40
191	<i>N</i> -Aryl Mercaptopropionamides as Broad-Spectrum Inhibitors of Metallo- $\beta$ -Lactamases. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3913-3922.	2.9	11
192	Prevalence of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infection in a Northern Province in China: Clinical Characteristics, Drug Resistance, and Geographic Distribution. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 569-579.	1.1	18
193	The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0216821.	1.4	11
194	Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant <i>Escherichia coli</i> collected from four geographic regions, 2012-2018. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, 13.	1.7	2
195	Structural Characterization of the D179N and D179Y Variants of KPC-2 $\beta$ -Lactamase: $\Omega$ -Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0241421.	1.4	22
196	Re-sensitization of <i>mcr</i> carrying multidrug resistant bacteria to colistin by silver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119417119.	3.3	15
198	<i>Klebsiella pneumoniae</i> Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0217921.	1.4	10
199	Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2022, 34, e00728.	2.1	17
200	Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as $\beta$ -lactamase inhibitors. <i>Scientific Reports</i> , 2022, 12, 5510.	1.6	4
201	Broad-spectrum cyclic boronate $\beta$ -lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 62, 116722.	1.4	2
202	Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 103, 115673.	0.8	2
203	QM/MM Study of a VIM-1 Metallo- $\beta$ -Lactamase Enzyme: The Catalytic Reaction Mechanism. <i>ACS Catalysis</i> , 2022, 12, 36-47.	5.5	9
204	Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. <i>Antibiotics</i> , 2021, 10, 1506.	1.5	21
205	In vitro Bactericidal Activities of Combination Antibiotic Therapies Against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> With Different Carbapenemases and Sequence Types. <i>Frontiers in Microbiology</i> , 2021, 12, 779988.	1.5	5
206	Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR- <i>P. aeruginosa</i> ). <i>Clinical Infectious Diseases</i> , 2022, 75, 187-212.	2.9	182
207	Class C $\beta$ -Lactamases: Molecular Characteristics. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0015021.	5.7	15

#	ARTICLE	IF	CITATIONS
208	Genomic Characterization of a Uropathogenic <i>Escherichia coli</i> ST405 Isolate Harboring blaCTX-M-15-Encoding IncFIA-FIB Plasmid, blaCTX-M-24-Encoding IncI1 Plasmid, and Phage-Like Plasmid. <i>Frontiers in Microbiology</i> , 2022, 13, 845045.	1.5	2
212	Reversing Multidrug-Resistant <i>Escherichia coli</i> by Compromising Its BAM Biogenesis and Enzymatic Catalysis through Microwave Hyperthermia Therapy. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	7
213	Antibiotic Resistance via Bacterial Cell Shape-Shifting. <i>MBio</i> , 2022, 13, .	1.8	23
214	Thiol targets in drug development to combat bacterial infections. , 2022, , 679-711.		0
215	Coexistence of blaNDM-1 and blaIMP-4 in One Novel Hybrid Plasmid Confers Transferable Carbapenem Resistance in an ST20-K28 <i>Klebsiella pneumoniae</i> . <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	8
216	Evolutionary Trajectories toward High-Level $\beta$ -Lactam/ $\beta$ -Lactamase Inhibitor Resistance in the Presence of Multiple $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	7
217	Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
218	Live-Cell Profiling of Penicillin-Binding Protein Inhibitors in <i>Escherichia coli</i> MG1655. <i>ACS Infectious Diseases</i> , 2022, 8, 1241-1252.	1.8	5
219	In vitro and in vivo activities of a novel $\beta$ -lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 31, 1-9.	0.9	7
220	Triazole-substituted phenylboronic acids as tunable lead inhibitors of KPC-2 antibiotic resistance. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114571.	2.6	2
221	Direct Colorimetry of Imipenem Decomposition as a Novel Cost-Effective Method for Detecting Carbapenemase-Producing Enterobacteria. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	0
222	Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam. <i>WIREs Mechanisms of Disease</i> , 2022, 14, .	1.5	10
223	Thieno[2,3- <i>cd</i> ]pyrimidine-Core Compounds Show Activity Against Clinically Relevant Gram-Positive Bacteria. <i>ChemMedChem</i> , 0, , .	1.6	0
224	A review of horses as a source of spreading livestock-associated methicillin-resistant <i>Staphylococcus aureus</i> to human health. <i>Veterinary World</i> , 0, , 1906-1915.	0.7	1
225	<i>Klebsiella pneumoniae</i> Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	36
226	The biogenesis of $\beta$ -lactamase enzymes. <i>Microbiology (United Kingdom)</i> , 2022, 168, .	0.7	7
227	Recent advances in $\beta$ -lactamase inhibitor chemotypes and inhibition modes. <i>European Journal of Medicinal Chemistry</i> , 2022, 242, 114677.	2.6	8
228	Discovery of environment-sensitive fluorescent probes for detecting and inhibiting metallo- $\beta$ -lactamase. <i>Bioorganic Chemistry</i> , 2022, 128, 106048.	2.0	1

#	ARTICLE	IF	CITATIONS
229	Design, Synthesis, and Biological Evaluation of New 1H-Imidazole-2-Carboxylic Acid Derivatives as Metallo- $\beta$ -Lactamase Inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 72, 116993.	1.4	3
230	The biochemistry and enzymology of zinc enzymes. , 2022, , .		1
231	Efficacy and safety of novel carbapenem- $\beta$ -lactamase inhibitor combinations: Results from phase II and III trials. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
232	Development of peptide-based metallo- $\beta$ -lactamase inhibitors as new strategy to combat antimicrobial resistance: A Mini-review. <i>Current Pharmaceutical Design</i> , 2022, 28, .	0.9	2
233	Emergence of a Fatal ST11-KL64 Tigecycline-Resistant Hypervirulent <i>Klebsiella pneumoniae</i> Clone Cocarrying <i>bla</i> and <i>NDM</i> and <i>KPC</i> in Plasmids. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
234	Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum- $\beta$ -Lactamase-Positive Clinical Isolates of <i>Enterobacterales</i> from a 2018-2020 Global Surveillance Collection. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	2
235	Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 791-823.	1.9	5
236	Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against <i>Enterobacterales</i> . <i>Microbiology Spectrum</i> , 0, , .	1.2	0
237	Evaluation of In Vitro Activity of Double-Carbapenem Combinations against KPC-2-, OXA-48- and NDM-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>Antibiotics</i> , 2022, 11, 1646.	1.5	2
238	Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo- $\beta$ -lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16392-16419.	2.9	11
239	Lead/Drug Discovery from Natural Resources. <i>Molecules</i> , 2022, 27, 8280.	1.7	9
240	Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16234-16251.	2.9	6
241	In vitro and computational studies of the $\beta$ -lactamase inhibition and $\beta$ -lactam potentiating properties of plant secondary metabolites. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 10326-10346.	2.0	1
242	Difference in the Inhibitory Effect of Thiol Compounds and Demetallation Rates from the Zn(II) Active Site of Metallo- $\beta$ -lactamases (IMP-1 and IMP-6) Associated with a Single Amino Acid Substitution. <i>ACS Infectious Diseases</i> , 2023, 9, 65-78.	1.8	2
243	Overcoming intrinsic resistance in gram-negative bacteria using small molecule adjuvants. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2023, 80, 129113.	1.0	10
244	Design, Synthesis, and Biological Evaluation of Boron-Containing $\beta$ -Lactamase Inhibitors: Closed-Loop Education Experiences in an Undergraduate Medicinal Chemistry Course. <i>Journal of Chemical Education</i> , 2023, 100, 803-810.	1.1	3
246	Chemical Basis of Combination Therapy to Combat Antibiotic Resistance. <i>Jacs Au</i> , 2023, 3, 276-292.	3.6	23
247	NDM-9 resistance to taniborbactam. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 401-402.	4.6	20



#	ARTICLE	IF	CITATIONS
248	Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018â€“2022). <i>Diagnostic Microbiology and Infectious Disease</i> , 2023, 106, 115945.	0.8	10
249	A new complex of silver(I) with probenecid: Synthesis, characterization, and studies of antibacterial and extended spectrum Î²-lactamases (ESBL) inhibition activities. <i>Journal of Inorganic Biochemistry</i> , 2023, 243, 112201.	1.5	0
250	Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC Î²-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study. <i>International Journal of Antimicrobial Agents</i> , 2023, 62, 106809.	1.1	6
251	Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019â€“2021). <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	13
252	Inhibition of Enzymatic Acetylation-Mediated Resistance to Plazomicin by Silver Ions. <i>Pharmaceuticals</i> , 2023, 16, 236.	1.7	1
253	Structural Insights for Î²-Lactam Antibiotics. <i>Biomolecules and Therapeutics</i> , 2023, 31, 141-147.	1.1	3
254	Ribosome-targeting antibiotics and resistance <i>via</i> ribosomal RNA methylation. <i>RSC Medicinal Chemistry</i> , 2023, 14, 624-643.	1.7	5
255	A new class A beta-lactamase gene blaCAE-1 coexists with blaAFM-1 in a novel untypable plasmid in <i>Comamonas aquatica</i> . <i>Scientific Reports</i> , 2023, 13, .	1.6	0
256	Long Term Characteristics of Clinical Distribution and Resistance Trends of Carbapenem-Resistant and Extended-Spectrum Î²-Lactamase <i>Klebsiella pneumoniae</i> Infections: 2014â€“2022. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1279-1295.	1.1	5
257	Estimation, Evaluation and Characterization of Carbapenem Resistance Burden from a Tertiary Care Hospital, Pakistan. <i>Antibiotics</i> , 2023, 12, 525.	1.5	4
258	Success stories of natural product-derived compounds from plants as multidrug resistance modulators in microorganisms. <i>RSC Advances</i> , 2023, 13, 7798-7817.	1.7	4
259	Antimicrobial peptides as promising antibiotic adjuvants to combat drug-resistant pathogens. <i>Critical Reviews in Microbiology</i> , 0, , 1-18.	2.7	7
260	Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance. <i>ACS Omega</i> , 2023, 8, 10757-10783.	1.6	21
261	Disc Diffusion and ComASPÂ® Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine. <i>Antibiotics</i> , 2023, 12, 604.	1.5	4
262	Genetic and biochemical characterization of BIM-1, a novel acquired subgroup B1 MBL found in a <i>Pseudomonas</i> sp. strain from the Brazilian Amazon region. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1359-1366.	1.3	4
263	Phenotypic Characterization and Antibiograms of Extended-Spectrum Beta-Lactamase-Producing <i>Escherichia coli</i> Isolated at the Human-Animal-Environment Interface Using a One Health Approach Among Households in Wakiso District, Uganda. <i>Infection and Drug Resistance</i> , 0, Volume 16, 2203-2216.	1.1	0
270	Making a chink in their armor: Current and next-generation antimicrobial strategies against the bacterial cell envelope. <i>Advances in Microbial Physiology</i> , 2023, , 221-307.	1.0	1
279	Benzoxaborole. , 2023, , 335-355.		0



#	ARTICLE	IF	CITATIONS
292	Challenges in the development of novel antibiotics. , 2023, , 65-85.		0
305	Antibiotic Resistance in Pathogens â€œ a Global Concern. , 2023, , 150-174.		0
309	Antimicrobial Resistance Profiles of Multidrug-Resistant Enterobacteria Isolated from Feces of Weaned Piglets. Current Microbiology, 2024, 81, .	1.0	0